Milestone Pharmaceuticals Inc.MISTNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank67
Year-over-Year Change
Year-over-year research & development expense growth
Latest
9.38%
↑ 115% vs avg
Percentile
P67
Within normal range
Streak
1 qtr
Consecutive growthAccelerating
Average
4.37%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | 9.38% |
| Q2 2025 | -26.30% |
| Q1 2025 | 24.29% |
| Q4 2024 | 1.06% |
| Q3 2024 | 40.78% |
| Q2 2024 | -22.64% |
| Q1 2024 | -33.03% |
| Q4 2023 | -19.15% |
| Q3 2023 | -22.05% |
| Q2 2023 | -15.94% |
| Q1 2023 | -4.27% |
| Q4 2022 | 9.04% |
| Q3 2022 | -7.80% |
| Q2 2022 | 21.54% |
| Q1 2022 | -19.58% |
| Q4 2021 | 9.77% |
| Q3 2021 | 4.40% |
| Q2 2021 | 10.69% |
| Q1 2021 | 49.06% |
| Q4 2020 | -32.32% |
| Q3 2020 | -2.01% |
| Q2 2020 | -26.76% |
| Q1 2020 | -16.09% |
| Q4 2019 | 48.23% |
| Q3 2019 | -9.33% |
| Q2 2019 | 35.57% |
| Q1 2019 | 6.41% |
| Q4 2018 | 86.58% |
| Q3 2018 | 53.31% |
| Q2 2018 | -17.47% |
| Q1 2018 | 0.00% |